Answers are grounded in this paper and cite their sources.
In August 2017, the FDA took historic action in granting the first approval of gene therapy to tisagenlecleucel. This landmark step brought CAR T-cell therapy to the commercial space and heralded a new era in managing refractory B-cell malignancies and FDA oversight of gene-modified therapies.See related article by O'Leary et al., p. 1142.
No takes yet. Share an insight, caveat, or question.
Mark B. Geyer (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: